![Min-Chul Park](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Min-Chul Park
Directeur/Membre du Conseil chez ZYVERSA THERAPEUTICS, INC.
Fortune : - $ au 31/05/2024
Profil
Min-Chul Park is the founder of Tme Therapeutics, Inc. He currently holds the position of Chief Executive Officer & Director at Curebio Therapeutics, Director at ZyVersa Therapeutics Operating, Inc., Independent Director at ZyVersa Therapeutics, Inc., and Assistant Professor at Inje University.
Previously, he served as Chief Executive Officer & Director at Neomics Co., Ltd., Chief Executive Officer & Director at CURE BIO Co., Ltd., and Senior Research Associate at Seoul National University.
He obtained his doctorate degree from Seoul National University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
21/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Min-Chul Park
Sociétés | Poste | Début |
---|---|---|
ZYVERSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2022 |
ZyVersa Therapeutics Operating, Inc.
![]() ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Directeur/Membre du Conseil | - |
Inje University | Corporate Officer/Principal | - |
Anciens postes connus de Min-Chul Park
Sociétés | Poste | Fin |
---|---|---|
CURE BIO Co., Ltd.
![]() CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Directeur Général | 01/04/2022 |
Neomics Co., Ltd.
![]() Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Directeur Général | - |
Formation de Min-Chul Park
Seoul National University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ZYVERSA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
ZyVersa Therapeutics Operating, Inc.
![]() ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
Neomics Co., Ltd.
![]() Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
CURE BIO Co., Ltd.
![]() CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Health Technology |